Payment processing giant, First Data, returned for a second round to the public markets. The company was acquired by KKR for $30B and currently carries more than $20B of debt on its books. As capital restructuring process is in place,
September 14, 2015
Central banks are like generals: they tend to fight the last war. The Great Financial meltdown of 2008 was centered in too big to fail, too big to jail transnational banks and other financial entities with enormous exposure to collateral risk (such as
Podcast: Play in new window | Play in new window (Duration: 13:16 — 6.1MB) DOW – 62 = 16,370 SPX – 8 = 1953 NAS + 26 = 4822 10 YR YLD un = 2.18% OIL – .49 = 44.14
Large amount of economic announcements During the session on Tuesday, we have quite a few economic announcements out, so we believe that there will be plenty of volatility in the marketplace in general. We have announcements coming out of both
Last Friday morning, my heart sank when I read Gartman had flip-flopped to bearish in “catholic terms” (whatever that means), and his actionable suggestion was to short the S&P futures. As required by federal statute, the market immediately exploded higher, and
The Chart of the Day belongs to Ardelyx (NASDAQ:ARDX). I found the biopharmaceutical company by using Barchart to sort the Russell 3000 Index stocks first for the highest Barchart technical buy signals then again for a Weighted Alpha of 50.00+
Does [China’s] shift from a manufacturing-driven economy to a service-driven one make macroeconomic shocks like those seen this summer inevitable? Peter Fuhrman: China has enjoyed something of a worldwide monopoly on hair-raising economic news of late: a stock market collapse
The valuation question, which has dogged Starbucks (SBUX) seemingly forever, takes on particular meaning for me now since the stock appeared as one of 16 holdings in the Low-Volatility S&P 500 strategy I maintain on Portfolio123’s Ready-to-Go platform. How, one
Penumbra, Inc. is scheduled to IPO on Friday, Sept. 18. We were impressed by the Penumbra (NYSE:PEN) neuro and vascular technologies demonstrated in their roadshow. Combined with their meaningful revenue ($125M in 2014 which was up 41%) and profitability, this
Shares of Raptor Pharmaceuticals (RPTP) closed down 37.49% today after the company announced that it failed a phase 2b liver study in children. More specifically the targeted disease in these children is nonalcoholic steatohepatitis — NASH. As the name suggests
